Literature DB >> 24648001

Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease.

Francesca L'Episcopo1, Cataldo Tirolo, Nunzio Testa, Salvatore Caniglia, Maria Concetta Morale, Maria Francesca Serapide, Stefano Pluchino, Bianca Marchetti.   

Abstract

Wnt/β-catenin signaling is required for specification and neurogenesis of midbrain dopaminergic (mDA) neurons, the pivotal neuronal population that degenerates in Parkinson's disease (PD), and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Wnt/β-catenin signaling plays a vital role in adult neurogenesis but whether it might engage DA neurogenesis/neurorepair in the affected PD brain is yet unresolved. Recently, the adult midbrain aqueduct periventricular regions (Aq-PVRs) were shown to harbor multipotent clonogenic neural stem/progenitor cells (mNPCs) with DA potential in vitro, but restrictive mechanisms in vivo are believed to limit their DA regenerative capacity. Using in vitro mNPC culture systems we herein demonstrate that aging is one most critical factor restricting mNPC neurogenic potential via dysregulation of Wnt/β-catenin signaling. Coculture paradigms between young/aged (Y/A) mNPCs and Y/A astrocytes identified glial age and a decline of glial-derived factors including Wnts as key determinants of impaired neurogenic potential, whereas Wnt activation regimens efficiently reversed the diminished proliferative, neuronal, and DA differentiation potential of A-mNPCs. Next, in vivo studies in wild (Wt) and transgenic β-catenin reporter mice uncovered Wnt/β-catenin signaling activation and remarkable astrocyte remodeling of Aq-PVR in response to MPTP-induced DA neuron death. Spatio-temporal analyses unveiled β-catenin signaling in predopaminergic (Nurr1(+)/TH(-)) and imperiled or rescuing DAT(+) neurons during MPTP-induced DA neuron injury and self-repair. Aging inhibited Wnt signaling, whereas β-catenin activation in situ with a specific GSK-3β antagonist promoted a significant degree of DA neurorestoration associated with reversal of motor deficit, with implications for neurorestorative approaches in PD.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Adult stem/neuroprogenitors; Aging; Dopaminergic plasticity; Neuroprotection; Neurorepair; Parkinson's disease; Wnt/β-catenin signaling

Mesh:

Year:  2014        PMID: 24648001      PMCID: PMC4106883          DOI: 10.1002/stem.1708

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  80 in total

Review 1.  Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.

Authors:  E Bezard; C E Gross
Journal:  Prog Neurobiol       Date:  1998-06       Impact factor: 11.685

2.  Possibility for neurogenesis in substantia nigra of parkinsonian brain.

Authors:  Kenji Yoshimi; Yong-Ri Ren; Tatsunori Seki; Masanori Yamada; Hideki Ooizumi; Masafumi Onodera; Yuko Saito; Shigeo Murayama; Hideyuki Okano; Yoshikuni Mizuno; Hideki Mochizuki
Journal:  Ann Neurol       Date:  2005-07       Impact factor: 10.422

Review 3.  Restorative approaches in Parkinson's Disease: which cell type wins the race?

Authors:  Anne K Meyer; Martina Maisel; Andreas Hermann; Katja Stirl; Alexander Storch
Journal:  J Neurol Sci       Date:  2009-09-04       Impact factor: 3.181

4.  Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.

Authors:  Wenya Wang; Yi Yang; Chunyi Ying; Wenming Li; Haolan Ruan; Xiaonan Zhu; Yan You; Yifan Han; Ruzhu Chen; Yizheng Wang; Mingtao Li
Journal:  Neuropharmacology       Date:  2007-04-19       Impact factor: 5.250

5.  Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Authors:  Maria Sundberg; Helle Bogetofte; Tristan Lawson; Johan Jansson; Gaynor Smith; Arnar Astradsson; Michele Moore; Teresia Osborn; Oliver Cooper; Roger Spealman; Penelope Hallett; Ole Isacson
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

6.  Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors.

Authors:  Silvia Maretto; Michelangelo Cordenonsi; Sirio Dupont; Paola Braghetta; Vania Broccoli; A Bassim Hassan; Dino Volpin; Giorgio M Bressan; Stefano Piccolo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

Review 7.  Clinical application of stem cell therapy in Parkinson's disease.

Authors:  Marios Politis; Olle Lindvall
Journal:  BMC Med       Date:  2012-01-04       Impact factor: 8.775

8.  Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons.

Authors:  Agnès Petit-Paitel; Frédéric Brau; Julie Cazareth; Joëlle Chabry
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

Review 9.  Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.

Authors:  Francesca L'Episcopo; Cataldo Tirolo; Salvo Caniglia; Nuccio Testa; Maria Concetta Morale; Maria Francesca Serapide; Stefano Pluchino; Bianca Marchetti
Journal:  J Mol Cell Biol       Date:  2014-01-14       Impact factor: 6.216

Review 10.  Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair.

Authors:  Bianca Marchetti; Francesca L'Episcopo; Maria Concetta Morale; Cataldo Tirolo; Nuccio Testa; Salvo Caniglia; Maria Francesca Serapide; Stefano Pluchino
Journal:  Eur J Neurosci       Date:  2013-03-05       Impact factor: 3.386

View more
  34 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Genomic convergence of locus-based GWAS meta-analysis identifies AXIN1 as a novel Parkinson's gene.

Authors:  Mohammad Saeed
Journal:  Immunogenetics       Date:  2018-06-19       Impact factor: 2.846

Review 3.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

Review 4.  Pluripotent stem cells progressing to the clinic.

Authors:  Alan Trounson; Natalie D DeWitt
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03       Impact factor: 94.444

Review 5.  Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.

Authors:  Bianca Marchetti; Cataldo Tirolo; Francesca L'Episcopo; Salvatore Caniglia; Nunzio Testa; Jayden A Smith; Stefano Pluchino; Maria F Serapide
Journal:  Aging Cell       Date:  2020-02-12       Impact factor: 9.304

6.  Nurr1 promotes intestinal regeneration after ischemia/reperfusion injury by inhibiting the expression of p21 (Waf1/Cip1).

Authors:  Guo Zu; Jihong Yao; Anlong Ji; Shili Ning; Fuwen Luo; Zhenlu Li; Dongcheng Feng; Yiqi Rui; Yang Li; Guangzhi Wang; Xiaofeng Tian
Journal:  J Mol Med (Berl)       Date:  2016-08-24       Impact factor: 4.599

Review 7.  Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review.

Authors:  Niraj Kumar Jha; Wei-Chih Chen; Sanjay Kumar; Rajni Dubey; Lung-Wen Tsai; Rohan Kar; Saurabh Kumar Jha; Piyush Kumar Gupta; Ankur Sharma; Rohit Gundamaraju; Kumud Pant; Shalini Mani; Sandeep Kumar Singh; Ricardo B Maccioni; Tirtharaj Datta; Sachin Kumar Singh; Gaurav Gupta; Parteek Prasher; Kamal Dua; Abhijit Dey; Charu Sharma; Yasir Hayat Mughal; Janne Ruokolainen; Kavindra Kumar Kesari; Shreesh Ojha
Journal:  Open Biol       Date:  2022-03-16       Impact factor: 6.411

Review 8.  Drugs and Endogenous Factors as Protagonists in Neurogenic Stimulation.

Authors:  Raphaela A Chiareli; Bruno L Marques; Gustavo A de Carvalho; Raysa T V de Souza; Pedro H G Santana; Helton C Santiago; Mauro C X Pinto; Alexander Birbrair; Ricardo C Parreira; Henning Ulrich; Rodrigo R Resende
Journal:  Stem Cell Rev Rep       Date:  2022-08-12       Impact factor: 6.692

Review 9.  Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.

Authors:  Parisa Farzanehfar
Journal:  Neurochem Res       Date:  2016-09-10       Impact factor: 3.996

10.  Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease.

Authors:  Xin Wang; Nuomin Li; Nian Xiong; Qi You; Jie Li; Jinlong Yu; Hong Qing; Tao Wang; Heather J Cordell; Ole Isacson; Jeffery M Vance; Eden R Martin; Ying Zhao; Bruce M Cohen; Edgar A Buttner; Zhicheng Lin
Journal:  Mol Neurobiol       Date:  2016-03-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.